Welcome to our dedicated page for BLDEW SEC filings (Ticker: BLDEW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on BLDEW's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into BLDEW's regulatory disclosures and financial reporting.
Strata Critical Medical, Inc. Chief Accounting Officer Amir Cohen sold 14,306 shares of Class A common stock on May 11, 2026 in an open-market sale at a weighted average price of $5.79 per share. The transaction was executed under a Rule 10b5-1 trading plan adopted on December 10, 2025. Following this sale, Cohen directly holds 202,138 shares of the company’s Class A common stock.
Strata Critical Medical, Inc. Chief Accounting Officer Amir Cohen sold 14,306 shares of Class A common stock on May 11, 2026 in an open-market sale at a weighted average price of $5.79 per share. The transaction was executed under a Rule 10b5-1 trading plan adopted on December 10, 2025. Following this sale, Cohen directly holds 202,138 shares of the company’s Class A common stock.
Morgan Stanley Smith Barney LLC submitted a Form 144 notice relating to proposed sales of Common stock tied to equity awards for the issuer with ticker BLDE. The excerpt lists 23,899 Restricted Stock Units dated 09/08/2024 and 41,282 Performance Stock Units dated 03/08/2025. The filing references 05/11/2026 and NASDAQ in the header.
Morgan Stanley Smith Barney LLC submitted a Form 144 notice relating to proposed sales of Common stock tied to equity awards for the issuer with ticker BLDE. The excerpt lists 23,899 Restricted Stock Units dated 09/08/2024 and 41,282 Performance Stock Units dated 03/08/2025. The filing references 05/11/2026 and NASDAQ in the header.
Velibor Krstic filed Amendment No. 3 to a Schedule 13D regarding Strata Critical Medical, Inc., reporting that 1,577,500 warrants to purchase Class A common stock (SRTAW) expired worthless on May 7, 2026.
Following this expiration, Krstic now beneficially owns 0 warrants, representing 0.0% of the warrant class, and therefore ceased to be a beneficial owner of more than five percent of these securities. The warrants had originally been purchased with personal funds, and no cash or other consideration was involved in their expiration.
Velibor Krstic filed Amendment No. 3 to a Schedule 13D regarding Strata Critical Medical, Inc., reporting that 1,577,500 warrants to purchase Class A common stock (SRTAW) expired worthless on May 7, 2026.
Following this expiration, Krstic now beneficially owns 0 warrants, representing 0.0% of the warrant class, and therefore ceased to be a beneficial owner of more than five percent of these securities. The warrants had originally been purchased with personal funds, and no cash or other consideration was involved in their expiration.
Strata Critical Medical, Inc. reported that Velibor Krstic, a ten percent owner, had 1,577,500 warrants to purchase Class A Common Stock expire. These warrants, exercisable at $11.50 per share, expired worthless on May 7, 2026 under a Warrant Agreement dated September 12, 2019. Following the expiration, no warrants of this series remain held by the reporting person.
Strata Critical Medical, Inc. reported that Velibor Krstic, a ten percent owner, had 1,577,500 warrants to purchase Class A Common Stock expire. These warrants, exercisable at $11.50 per share, expired worthless on May 7, 2026 under a Warrant Agreement dated September 12, 2019. Following the expiration, no warrants of this series remain held by the reporting person.
Strata Critical Medical, Inc. notified the Nasdaq Stock Market LLC of the removal of its warrants expiring 05/07/2026 from listing and/or registration under Section 12(b) of the Exchange Act. The notice cites compliance with Rule 17 CFR 240.12d2-2 and indicates the exchange and issuer followed the voluntary withdrawal procedures.
Strata Critical Medical, Inc. notified the Nasdaq Stock Market LLC of the removal of its warrants expiring 05/07/2026 from listing and/or registration under Section 12(b) of the Exchange Act. The notice cites compliance with Rule 17 CFR 240.12d2-2 and indicates the exchange and issuer followed the voluntary withdrawal procedures.
Strata Critical Medical delivered strong growth and turned profitable in the quarter ended March 31, 2026. Revenue rose to $67.4 million from $35.9 million, driven by 32.4% growth in Logistics to $47.6 million and new Clinical revenue of $19.8 million from the Keystone acquisition.
Gross profit doubled to $14.1 million, lifting total gross margin to 21.0% as higher‑margin Clinical work scaled. After $5.4 million of other non‑operating income, mainly fair value changes, Strata posted net income of $2.2 million versus a $3.5 million loss a year earlier, including a small loss from discontinued Passenger operations.
The company ended the quarter with $58.7 million in cash and cash equivalents, total assets of $327.6 million and stockholders’ equity of $285.7 million. A new $30 million asset‑based revolving credit facility was put in place and remained undrawn, providing additional liquidity for working capital and growth.
Strata Critical Medical delivered strong growth and turned profitable in the quarter ended March 31, 2026. Revenue rose to $67.4 million from $35.9 million, driven by 32.4% growth in Logistics to $47.6 million and new Clinical revenue of $19.8 million from the Keystone acquisition.
Gross profit doubled to $14.1 million, lifting total gross margin to 21.0% as higher‑margin Clinical work scaled. After $5.4 million of other non‑operating income, mainly fair value changes, Strata posted net income of $2.2 million versus a $3.5 million loss a year earlier, including a small loss from discontinued Passenger operations.
The company ended the quarter with $58.7 million in cash and cash equivalents, total assets of $327.6 million and stockholders’ equity of $285.7 million. A new $30 million asset‑based revolving credit facility was put in place and remained undrawn, providing additional liquidity for working capital and growth.
Strata Critical Medical reported strong first quarter 2026 results, with total revenue rising 87.4% year-over-year to $67.4 million, driven by 32.4% growth in Logistics revenue and the addition of its Clinical business. Gross profit doubled to $14.1 million, lifting gross margin to 21.0% from 19.6%.
The company generated net income from continuing operations of $2.4 million, compared with a loss of $1.6 million a year earlier, and delivered Adjusted EBITDA of $6.4 million, up sharply from $0.4 million. Operating cash flow reached $3.9 million, and Strata ended the quarter with $58.8 million in cash and short-term investments.
Clinical revenue rose 12.7% sequentially to $19.8 million, with Clinical gross profit up 29.2% versus Q4 2025. The company completed a bolt-on acquisition of Ohio Valley Perfusion Associates and reiterated its full-year 2026 guidance for revenue of $260–275 million, Adjusted EBITDA of $29–33 million, and free cash flow before aircraft and engine acquisitions of $15–22 million.
Strata Critical Medical reported strong first quarter 2026 results, with total revenue rising 87.4% year-over-year to $67.4 million, driven by 32.4% growth in Logistics revenue and the addition of its Clinical business. Gross profit doubled to $14.1 million, lifting gross margin to 21.0% from 19.6%.
The company generated net income from continuing operations of $2.4 million, compared with a loss of $1.6 million a year earlier, and delivered Adjusted EBITDA of $6.4 million, up sharply from $0.4 million. Operating cash flow reached $3.9 million, and Strata ended the quarter with $58.8 million in cash and short-term investments.
Clinical revenue rose 12.7% sequentially to $19.8 million, with Clinical gross profit up 29.2% versus Q4 2025. The company completed a bolt-on acquisition of Ohio Valley Perfusion Associates and reiterated its full-year 2026 guidance for revenue of $260–275 million, Adjusted EBITDA of $29–33 million, and free cash flow before aircraft and engine acquisitions of $15–22 million.
Strata Critical Medical reports that ARK Investment Management LLC and Catherine D. Wood beneficially own 7,455,284 shares of Common Stock, representing 8.57% of the class.
The filing allocates voting and dispositive authority: ARK holds sole voting and sole dispositive power over 7,455,284 shares while Catherine D. Wood holds shared voting and shared dispositive power over 7,455,284 shares. The Schedule 13G/A is signed and dated 04/30/2026.
Strata Critical Medical reports that ARK Investment Management LLC and Catherine D. Wood beneficially own 7,455,284 shares of Common Stock, representing 8.57% of the class.
The filing allocates voting and dispositive authority: ARK holds sole voting and sole dispositive power over 7,455,284 shares while Catherine D. Wood holds shared voting and shared dispositive power over 7,455,284 shares. The Schedule 13G/A is signed and dated 04/30/2026.
Strata Critical Medical, Inc. CEO, Logistics Scott M. Wunsch reported equity compensation activity involving Class A common stock. On April 23, 2026, he acquired 57,172 shares at $0.0000 per share as a grant tied to performance-based restricted stock units that vested after meeting certified performance criteria.
On April 24, 2026, the company withheld 13,922 shares at $4.92 per share to cover tax obligations related to the PSU vesting, a non-market disposition. Following these transactions, he held 631,124 shares directly and 382,987 shares indirectly through a limited liability company he solely owns.
Strata Critical Medical, Inc. CEO, Logistics Scott M. Wunsch reported equity compensation activity involving Class A common stock. On April 23, 2026, he acquired 57,172 shares at $0.0000 per share as a grant tied to performance-based restricted stock units that vested after meeting certified performance criteria.
On April 24, 2026, the company withheld 13,922 shares at $4.92 per share to cover tax obligations related to the PSU vesting, a non-market disposition. Following these transactions, he held 631,124 shares directly and 382,987 shares indirectly through a limited liability company he solely owns.
Strata Critical Medical, Inc. Chief Accounting Officer Amir Cohen reported compensation-related equity activity involving performance-based restricted stock units (PSUs). On April 23, he acquired 83,505 shares of Class A common stock at no cost upon certification that PSU performance criteria from a March 20, 2025 grant were met. On April 24, 40,960 shares were withheld by the company at $4.92 per share to cover tax withholding obligations tied to the PSU vesting. After these routine award and tax-withholding entries, Cohen directly holds 216,444 shares of Class A common stock.
Strata Critical Medical, Inc. Chief Accounting Officer Amir Cohen reported compensation-related equity activity involving performance-based restricted stock units (PSUs). On April 23, he acquired 83,505 shares of Class A common stock at no cost upon certification that PSU performance criteria from a March 20, 2025 grant were met. On April 24, 40,960 shares were withheld by the company at $4.92 per share to cover tax withholding obligations tied to the PSU vesting. After these routine award and tax-withholding entries, Cohen directly holds 216,444 shares of Class A common stock.